Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) have been given a consensus rating of “Hold” by the six analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $6.00.

Several analysts have commented on the stock. Robert W. Baird assumed coverage on shares of Pieris Pharmaceuticals in a research note on Monday, May 13th. They issued an “outperform” rating and a $5.00 price target on the stock. Cowen reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Monday, May 13th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target (up previously from $5.00) on shares of Pieris Pharmaceuticals in a research note on Friday, May 10th. Zacks Investment Research cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 24th. Finally, ValuEngine cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 11th.

A number of hedge funds have recently made changes to their positions in PIRS. TIAA CREF Investment Management LLC increased its holdings in shares of Pieris Pharmaceuticals by 18.6% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 334,082 shares of the biotechnology company’s stock worth $1,871,000 after buying an additional 52,302 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Pieris Pharmaceuticals by 13.6% in the 3rd quarter. Vanguard Group Inc. now owns 370,616 shares of the biotechnology company’s stock worth $2,076,000 after buying an additional 44,335 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Pieris Pharmaceuticals by 589.9% in the 3rd quarter. Marshall Wace LLP now owns 161,078 shares of the biotechnology company’s stock worth $902,000 after buying an additional 137,730 shares during the last quarter. Vanguard Group Inc increased its holdings in shares of Pieris Pharmaceuticals by 13.6% in the 3rd quarter. Vanguard Group Inc now owns 370,616 shares of the biotechnology company’s stock worth $2,076,000 after buying an additional 44,335 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Pieris Pharmaceuticals by 433.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 769,551 shares of the biotechnology company’s stock worth $2,047,000 after buying an additional 625,351 shares during the last quarter. Institutional investors and hedge funds own 69.76% of the company’s stock.

PIRS stock traded down $0.22 during mid-day trading on Monday, hitting $3.59. The company had a trading volume of 267,220 shares, compared to its average volume of 371,933. The stock has a market cap of $187.27 million, a P/E ratio of -7.18 and a beta of 1.78. Pieris Pharmaceuticals has a 12-month low of $2.39 and a 12-month high of $6.55.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.05). The company had revenue of $4.91 million during the quarter, compared to analysts’ expectations of $6.92 million. Pieris Pharmaceuticals had a negative return on equity of 64.64% and a negative net margin of 84.75%. On average, research analysts forecast that Pieris Pharmaceuticals will post -0.86 EPS for the current fiscal year.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Story: What is a short straddle?

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.